- emergers.se - Page 3

NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play

2023-12-21• Analys, Research

Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of its activities...

Read More →

QLUCORE: Long term potential clouded by likely capital raise

2023-11-30• Analys, Research

With stable sales in H1’23/24, Qlucore has continued on the revised, more concentrated path announced in Q1, accompanied by a cost...

Read More →

GRANGEX: Pushing ahead with dual mines in the face of double delays

2023-11-22• Analys, Research

GRÄNGESBERG EXPLORATION Facing delays in both financing and operational development, the current cash at SEK 43.6m means that GRANGEX must...

Read More →

NANEXA: Raising our LOAs following a review of the projects

2023-11-21• Analys, Research

With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials...

Read More →

NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects

2023-11-01• Analys, Research

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.1%, Nanexa is...

Read More →

KEBNI: Mixed bag in Q3 – steep growth ahead

2023-11-01• Analys, Research

Despite 29% top-line growth in Q3’23, sales were a bit soft due to a slower-than-anticipated ramp-up of deliveries to Saab. This has led...

Read More →

KEBNI: Site visit provided clarity on scale-up and insight into ScaffSense venture

2023-10-16• Analys, Research

Our site visit to KebNi’s new production facility in Karlskoga not only showed production up and running, but also how it can scale...

Read More →

NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal

2023-10-11• Analys, Research

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has...

Read More →

NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025

2023-09-22• Analys, Research

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount. This will...

Read More →

QLUCORE: Streamlining focus to extend financial runway

2023-09-05• Analys, Research

In Q1’23/24, both sales of Qlucore Omics Explorer and costs were slightly higher than we expected. To extend its runway, Qlucore will...

Read More →

Författare: johan@emergers.se

NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play

QLUCORE: Long term potential clouded by likely capital raise

GRANGEX: Pushing ahead with dual mines in the face of double delays

NANEXA: Raising our LOAs following a review of the projects

NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects

KEBNI: Mixed bag in Q3 – steep growth ahead

KEBNI: Site visit provided clarity on scale-up and insight into ScaffSense venture

NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal

NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025

QLUCORE: Streamlining focus to extend financial runway

Widmark Research

CONTACT